复星医药(600196.SH):盐酸替那帕诺片上市许可申请获批

智通财经
26 Feb

智通财经APP讯,复星医药(600196.SH)发布公告,公司控股子公司上海复星医药产业发展有限公司(简称“复星医药产业”)获许可产品盐酸替那帕诺片(中国境内1商品名:万缇乐®)的上市许可申请于近日获国家药品监督管理局批准,本次获批适应症为用于控制对磷结合剂疗效不充分或不耐受的慢性肾脏病(CKD)成人透析患者的血清磷水平。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10